METABOLISM DRUGS MARKET ANALYSIS

Metabolism diseases results from malfunctioning or inadequate function of the body’s original metabolism. Metabolism diseases can also have a genetic origin, as they can be caused by genetic birth defects as well. Metabolic diseases from genetic defects have low incidence and prevalence rate. Metabolism involves breaking down of carbohydrates, proteins, and fats present in the consumed food, to generate energy. Furthermore, metabolism also involves excretion of nitrogen through urine, and breaking down or converting other substances and chemicals. This metabolism is carried out by certain enzymes and proteins designated for the respective role.

The global metabolism drugs market is estimated to be valued at US$ 7,685.0 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030).

Figure 1. Global Metabolism Drugs Market Share (%), by Therapy Type, 2022

To learn more about this report, request a free sample copy

The increasing product approval by regulatory authorities is expected to drive the growth of the global metabolism drugs market

The increasing product approval by regulatory authorities is expected to drive the growth of the global metabolism drugs market. For instance, on February 17, 2022, Agios Pharmaceuticals, Inc., a company in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced that the U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, debilitating, lifelong hemolytic anemia. PYRUKYND is a first-in-class, oral PK activator and the first approved disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase (PK) deficiency disease.

Figure 2.Global Metabolism Drugs Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Increasing research and development for developing metabolism drugs is expected to drive the market growth

Increasing research and development for development metabolism drugs is expected to drive the market growth over the forecast period. For instance, on May 15, 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced positive initial data from the confirmatory third cohort and longer-term data from the first two cohorts of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus (AAV) based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa).

Global Metabolism Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another place which affected the research and development activities for metabolism drugs development.

Global Metabolism Drugs Market: Key Developments

On February 17, 2022, Maze Therapeutics, a company translating genetic insights into new precision medicines, announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers. MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the potential oral treatment of patients with late-onset Pompe disease.

Global Metabolism Drugs Market: Restraint

The major factors that hinder the growth of the global metabolism drugs market include clinical hold on trials by market players. For instance, on June 26, 2022, Astellas Pharma Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants. FORTIS is a clinical trial evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement therapy in adults with Late-Onset Pompe Disease.

Key Players

Major players operating in the global metabolism drugs market include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.